Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 10/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242715 | 1.00 | HTR2A (0.61) | HTR2AHTR2CNR3C1TSHRNOTUM | |
| SCHEMBL20425196 | 1.00 | HTR2A (0.61) | HTR2AHTR2CNR3C1TSHRNOTUM | |
| SCHEMBL21292889 | 0.85 | HTR2A (0.61) | HTR2ANR3C1TSHRMTNR1AMTNR1B | |
| SCHEMBL21292891 | 0.85 | HTR2A (0.61) | HTR2ANR3C1TSHRMTNR1AMTNR1B | |
| SCHEMBL27220732 | 0.84 | GPR84 (0.50) | HTR2AHTR2CNR3C1MTNR1AMTNR1B | |
| SCHEMBL27220736 | 0.84 | GPR84 (0.50) | HTR2AHTR2CNR3C1MTNR1AMTNR1B | |
| SCHEMBL27220733 | 0.84 | TACR1 (0.46) | NR3C1KDM4E | |
| SCHEMBL27220730 | 0.84 | TACR1 (0.46) | NR3C1KDM4E | |
| SCHEMBL25001307 | 0.83 | HTR2A (0.54) | HTR2AHTR2CNR3C1TSHRNOTUM | |
| SCHEMBL21483315 | 0.83 | HTR2A (0.54) | HTR2AHTR2CNR3C1TSHRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | HTR2A 3134/4885HTR2C 2543/4885NR3C1 2102/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | HTR2A 3059/4885HTR2C 2709/4885NR3C1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.